QUOTE AND NEWS
newratings.com  Mar 29  Comment 
WASHINGTON (dpa-AFX) - Affymetrix Inc. (AFFX) said that it determined that the unsolicited merger proposal submitted by Origin Technologies Corporation, LLC on March 22, 2016 does not constitute a Superior Proposal, as defined in Affymetrix'...
newratings.com  Mar 23  Comment 
WASHINGTON (dpa-AFX) - Responding to Origin Technologies' most recent proposal to acquire Affymetrix Inc. (AFFX), Thermo Fisher Scientific Inc. (TMO) said that it remains confident that origin technologies' proposal is not likely to...
Forbes  Mar 22  Comment 
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Thermo Fisher Scientific (TMO) is now the #25 analyst pick, moving up by 1 spot.
newratings.com  Mar 22  Comment 
WASHINGTON (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) reiterated its belief that the merger agreement between the company and Affymetrix is superior and remains in the best interest of Affymetrix and its stockholders. Thermo Fisher management...
New York Times  Mar 21  Comment 
The company said the offer, which was meant to derail its sale to Thermo Fisher Scientific, was not a “superior proposal” to the Thermo Fisher deal.
New York Times  Mar 18  Comment 
The offer to buy Affymetrix, a maker of genetic analysis technology, for $1.5 billion tops an existing takeover proposal by Thermo Fisher Scientific.
Reuters  Mar 18  Comment 
A group of former Affymetrix Inc executives offered to buy the gene testing and analysis company for about $1.5 billion, looking to trump a deal with Thermo Fisher Scientific Inc.
Forbes  Mar 9  Comment 
Looking at the universe of stocks we cover at Dividend Channel, on 3/11/16, Thermo Fisher Scientific Inc (NYSE: TMO), Conmed Corp. (NASD: CNMD), and Merck & Co., Inc (NYSE: MRK) will all trade ex-dividend for their respective upcoming dividends....
Benzinga  Mar 4  Comment 
According to a recent article by Tara Lachapelle in Bloomberg, a recent filing by Thermo Fisher Scientific Inc. (NYSE: TMO) may suggest the company has something up its sleeves. The S-3ASR filings, from Tuesday, could imply, according to...




 
TOP CONTRIBUTORS

Thermo Fisher Scientific (NYSE:TMO) is a one-stop supplier for research labs around the world. Fisher Scientific's 100-year-old business as the top seller of core laboratory consumable products which are crucial to every research lab complements Thermo Electron's sales of high-tech bioanalytic instruments, which are an expensive one-time purchase but require consumables to operate.

Its diverse portfolio of products also shields TMO from dependence on the spending patterns of its customers and their public and private funders. The sales of core lab consumables (unlike bioanalytic equipment) do not depend on fluctuating research budgets, providing TMO with protection against these fluctuations.

Company Overview

Business Financials

In 2009, TMO earned a total of $10.1 billion in total revenues. This was a decline from its 2008 total revenues of $10.6 billion. Unsurprisingly, as a result in the decline in revenues TMO's net income was adversely affected. Between 2008 and 2009, TMO's net income declined from $989 million in 2008 to $850 million in 2009.[1]

Business Segments

Thermo Fisher Scientific is the result of a 2006 merger between Thermo Electron and Fisher Scientific. TMO's business is now divided into two main segments:

Analytical Technologies

This segment sells lab instruments, diagnostic devices, software and services to pharmaceutical, biotechnology, and academic laboratories. This segment has continued the business of Thermo Electron before the merger. In addition, TMO develops and sells high-tech detection equipment for uses in air quality monitoring, radiation detection, as well as equipment used in safety monitoring at airports and border patrols for the prevention of terrorism. [2]

Laboratory Products and Services

This segment sells consumables that are disposable commodities used in the everyday operations of labs. This segment has continued the core business of Fisher Scientific before the merger and still maintains a separate website to maintain customer loyalty. The Fisher Scientific catalog has been published for over 100 years and is the largest provider of core laboratory equipment and services to research labs around the world. [3]

Trends and Forces

TMO's Bioanalytic instruments face are becoming outdated

TMO's bioanalytic technologies division faces significant competition from many other firms that specialize in producing innovative bioanalytic instruments. Specifically, key competitor Agilent Technologies (A) has actively produced new mass spectrometry technologies, while TMO has focused on developing new chromatography equipment while maintaining its current technology for mass spectrometry analytic instruments. If the firm cannot develop a suitable competitor to Agilon's product, TMO may see a loss of sales revenue in the analytic technologies division as potential customers opt for the newer technology. [4]

Core lab consumables face commoditization and increased competition

Fisher Scientific's laboratory consumables catalog has been published for over 100 years, and its products before the TMO merger had a loyal following in research institutions around the world. The merger with Thermo Electron placed pressure on this brand reputation, while the low costs of producing these products invites increasing competition. Specifically its main competitor VWR International threatens to take market share. Customer loyalty is very important in the laboratory consumables business, where the products are essentially commodities that differ only in brand name.

TMO's sensitive detection equipment is exposed to liability issues

TMO currently provides detection equipment in various airports, embassies, border crossings, etc., for protection against explosives and prevention of terrorist acts . [5] Malfunction of this equipment could cause such restricted materials to pass through undetected and incur liability claims against TMO. TMO's current liability insurance does not cover against such claims; additionally, TMO may lose a large part of their clientele if such a product malfunction were to become publicized. [6]

TMO revenues will fluctuate according to capital spending patterns of customers

TMO's customers often stock up on lab consumables and equipment at the end of the year, when funding is abundant (NIH funding is distributed to labs towards the end of the calendar year). TMO's revenues thus fluctuate throughout the year and are strongest in the last quarter of the calendar year. NIH funding is not completely stable, either - economic pressures may result in a stagnation of NIH funding, which has been growing at 2-3% in the past few years but is not expected to increase in the near future. TMO's customers from academic and government research labs are directly affected by the limitations of NIH grant funding; a lack of funding results in fewer laboratory product and equipment purchases and adversely affects TMO's sales revenues. [7]

Competition and Market Share

TMO's two main product divisions, analytic technologies and consumable laboratory products, are in direct competition with many other companies in the industry. In particular, its portfolio of bioanalytic instruments faces stiff competition. However, it is the top seller in consumable laboratory equipment, with only one other significant competitor. Some of its top competitors include Agilent Technologies (A), Becton, Dickinson and Company (BDX), and Beckman Coulter (BEC).

hi augusta, Everyone does this type of thing diflerentfy so I don't exactly know what you mean by margin of safety. Basically using a P/E of 11x and an EPS growth rate of 9%, I get $48.41 as a fair price to pay for Sun Life. So I guess $45.00 would be a margin of safety of 7% and the price i actually bought at ($38.60) would be a MOS of 20%.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki